Municipality-Specific Determinants of Chronic Kidney Disease in Southern Libya: Comparative Analysis of Clinical, Behavioral, and Environmental Risk Factors"
DOI:
https://doi.org/10.54361/LJMR.19.2.54Keywords:
Chronic Kidney Disease, Diabetes Mellitus, Hypertension, Environmental Risk, Southern Libya, Targeted PreventionAbstract
Background: Chronic Kidney Disease (CKD) poses a major public health challenge worldwide, with Diabetes Mellitus (DM) and Hypertension (HTN) being the leading drivers of progression to End-Stage Renal Disease (ESRD). In Southern Libya, preliminary reports from Tasawa, Al-Qatrun, Traghen and Obari indicate an alarming rise in ESRD cases requiring dialysis.Objective: This study aims to compare clinical, behavioral, and environmental determinants of CKD across four Southern Libyan municipalities, identifying localized high-risk patterns to inform targeted prevention strategies.Methods: An integrated risk-assessment framework was applied, evaluating clinical factors (glycemic and blood pressure control), behavioral factors (obesity, chronic analgesic use, herbal remedies), and environmental exposures (groundwater quality, Total Dissolved Solids [TDS]). Comparative analyses were conducted to detect inter-municipality variations in CKD risk profiles. Results: Preliminary findings suggest heterogeneous distribution of risk factors, with specific municipalities exhibiting higher prevalence of uncontrolled DM, HTN, obesity, and exposure to poor-quality drinking water.Conclusion: Municipality-specific risk profiling provides essential evidence for targeted interventions and early CKD prevention strategies, reducing progression to ESRD in resource-limited settings.
Downloads
References
1. Ashur ST, Shah SA, Riedat A, Habeb AM. Glycaemic control status among type 2 diabetic patients in Libya. Libyan J Med. 2016;11:31085. PMCID: PMC4803895.
2. Jayatilake N, Mendis S, Maheepala P, Mehta FR; CKDu National Research Project Team. Chronic kidney disease of uncertain aetiology: prevalence and causative factors in a developing country. BMC Nephrol. 2013;14:180. doi: 10.1186/1471-2369-14-180.
3. Johnson RJ, Wesseling C, Newman LS. Chronic Kidney Disease of Unknown Cause in Agricultural Communities. N Engl J Med. 2019;380(19):1843-1852. doi: 10.1056/NEJMra1813869.
4. Alashek WA, McIntyre CW, Taal MW. Epidemiology and aetiology of dialysis treated end stage kidney disease in Libya. BMC Nephrol. 2012;13:33. doi: 10.1186/1471-2369-13-33.
5. Al Ghamdi S, Al Ghamdi AS, Al-Ghamdi SMG, et al. Chronic kidney disease management in the Middle East & Africa: concerns and call to action. Int J Nephrol Renovasc Dis. 2023;16:1-11. doi: 10.2147/IJNRD.S394232.
6. Shirsat P, et al. Obesity and Chronic Kidney Disease: A Comprehensive Review. Healthcare. 2025;13(1):4. [MDPI].
7. Tabatabaei-Malazy O, Saeedi Moghaddam S, Keykhaei M, et al. Regional burden of chronic kidney disease in North Africa: a review. Front Public Health. 2022;10:1015902. doi: 10.3389/fpubh.2022.1015902.
8. Yim HE, Yoo KH. Obesity and chronic kidney disease: prevalence, implications and management in children and adolescents. Clin Exp Pediatr. 2021;64(2):70-78. doi: 10.3345/cep.2020.00164.
9. El-Reshaid W, Al-Sayed A, El-Reshaid K. Prevalence of obesity and risk of chronic kidney disease among young adults in Egypt. Indian J Nephrol. 2018;28(3):210-215. doi: 10.4103/ijn.IJN_169_17.
10. Polo V, García-Trabanino R, Rodriguez-Iturbe B. Mesoamerican nephropathy: what we know so far. Int J Nephrol. 2020;2020:8830231. PMCID: PMC7201734.
11. Perazella MA, Markowitz GS. Toxic nephropathies. Am J Kidney Dis. 2010;55(6):1020-1033. doi: 10.1053/j.ajkd.2010.02.344.
12. Xu X, Nie S, Chen G, et al. Nephrotoxicity of herbal medicine and its prevention. Front Pharmacol. 2020;11:582547. PMCID: PMC7593559.
13. World Health Organization. Guidelines for drinking-water quality: fourth edition incorporating the first addendum. Geneva: World Health Organization; 2017.
14. Chen Y, Wu G. Global, Regional, and National Burden of Chronic Kidney Disease Attributable to High Body Mass Index (BMI) among Individuals Aged 20–54 Years from 1990 to 2021: An Analysis of the Global Burden of Disease Study. Nutrients. 2025;17(1):112.
15. Roy M, Protity AT, Das S, Dhar P. Prevalence and Major Risk Factors of Non-communicable Diseases: A Machine Learning based Cross-Sectional Study. arXiv [Preprint]. 2023. arXiv:2305.12345.
16. Nguycharoen N. Explainable Machine Learning System for Predicting Chronic Kidney Disease in High-Risk Cardiovascular Patients. Diagnostics. 2024;14(3):284. doi: 10.3390/diagnostics14030284.
17. Al-Saeed AH, et al. Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide: A systematic review and meta-analysis. J Diabetes Res. 2022;2022:9920145.
18. Al-Homayani A, et al. Prevalence and assessment of risk factors of chronic kidney disease in Asir Region, Saudi Arabia. J Family Med Prim Care. 2021;10(2):671-677.
19. Okwuonu CG, et al. Prevalence and risk factors of chronic kidney disease in hypertensive patients in sub-Saharan Africa: A systematic review and meta-analysis. J Hum Hypertens. 2025;39(1):15-28.
20. Soderland P, Lovekar S, Weiner DE, et al. Chronic kidney disease of unknown etiology: risk factors for a global epidemic. Clin J Am Soc Nephrol. 2010;5(7):1252-1262.
21. Valcke M, et al. A review of molecular mechanisms linked to potential renal injury agents in tropical rural farming communities. Toxics. 2021;9(8):182. doi: 10.3390/toxics9080182.
22. Dharma-wardana MW. Food and water quality as determinants of chronic kidney disease of unknown etiology (CKDu) in Sri Lanka. Environ Sci Pollut Res Int. 2025;32(2):1204-1218.
23. Jager KJ, et al. Global health inequalities of chronic kidney disease: a meta-analysis. Lancet Public Health. 2024;9(3):e145-e158.
24. Mayo Clinic Staff. Chronic kidney disease: Symptoms and causes. Rochester (MN): Mayo Foundation for Medical Education and Research; 2023 [Accessed 2025 Dec 22]. Available from: https://www.mayoclinic.org.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ail Abd Alahrash, Abdusalam M. Abdull, Hind Ghaziti, Khaled. M.Aburas, Osama H. Almjdoub, Asmahan Abukhdir, Hajer Rashed, Nasrin Elfarrah, Salah Bahron (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
